broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K92723993-001-17-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.638283 | 1.154508 | 0.026454 | 0.878383 | 0.390402 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000955 |
BRD-K95142244-001-01-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.692744 | 1.080413 | 0.199929 | 0.782723 | 0.010017 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000955 |
BRD-K96123349-236-02-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.914861 | 0.008684 | -0.000635 | 0.957581 | 0.176119 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000955 |
BRD-K98572433-001-02-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.604263 | -4.161652 | 0.029638 | 0.993229 | 0.000609 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000955 |
BRD-K99616396-001-05-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.981707 | -1.063108 | 0.011053 | 0.989169 | 0.19326 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000955 |
BRD-K99749624-001-07-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.794083 | -1.23413 | 0.063198 | 0.960216 | 0.003656 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000955 |
BRD-M97302542-001-04-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.519764 | 0.785933 | 0.001678 | 0.889345 | 1.354934 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000955 |
BRD-A25234499-001-19-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.764585 | 3.20868 | 0.522792 | 1 | 7.788128 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000956 |
BRD-A70858459-001-01-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.193031 | -0.044249 | -0.006227 | 1 | 211.671451 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000956 |
BRD-A74914197-001-02-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.39219 | -0.244281 | -0.065208 | 1 | 0.000008 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000956 |
BRD-K02113016-001-19-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.317682 | 2.169535 | 0.076511 | 1 | 1.062769 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000956 |
BRD-K02130563-001-11-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.102703 | 0.9676 | 0.876283 | 0.397801 | 0.014168 | 0.017968 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000956 |
BRD-K03390685-001-01-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.73564 | 0.276162 | 0.075992 | 1 | 0.092898 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000956 |
BRD-K03406345-001-21-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.639093 | -0.387341 | -0.03267 | 0.877502 | 0.008842 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000956 |
BRD-K03449891-001-08-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.191605 | -0.237508 | -0.079172 | 1 | 0.327454 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000956 |
BRD-K03765900-001-01-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.870786 | -0.902714 | 0.054955 | 0.967482 | 0.004144 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000956 |
BRD-K05804044-001-18-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.355652 | 5.466089 | 0.191364 | 1 | 0.367591 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000956 |
BRD-K06814349-304-02-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.408135 | 3.790796 | 0.769478 | 0.854604 | 0.921819 | 1.441297 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000956 |
BRD-K08109215-001-06-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.447542 | 4.601436 | 0.592044 | 0.855628 | 0.791762 | 1.292366 | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000956 |
BRD-K08542803-001-02-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.287966 | 1.490389 | 0.768697 | 0.691037 | 0.148474 | 0.264016 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000956 |
BRD-K08547377-001-04-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.248329 | 3.822264 | 0.46522 | 0.642476 | 0.098933 | 0.118398 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000956 |
BRD-K08703257-001-13-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.0237 | -0.343 | -0.061771 | 1 | 0.102744 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000956 |
BRD-K08799216-001-05-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.24118 | -0.40896 | 0.273103 | 1 | 0.040547 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000956 |
BRD-K09951645-001-11-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.10594 | -4.075355 | -0.181916 | 1 | 0.075433 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000956 |
BRD-K11267252-001-05-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.572014 | 0.256297 | -0.01169 | 1 | 146.816005 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000956 |
BRD-K11630072-001-13-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.457167 | 5.342542 | 0.35018 | 0.924193 | 2.579159 | 4.085345 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000956 |
BRD-K12184916-001-19-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.601221 | -0.087097 | -0.164185 | 0.611142 | 206,057,260,372,442,000 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000956 |
BRD-K12343256-001-14-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.962117 | 0.496724 | 0.295061 | 1 | 0.120375 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000956 |
BRD-K13390322-001-06-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.876727 | 6.398507 | -0.092873 | 0.917494 | 0.015106 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000956 |
BRD-K13514097-001-04-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.647308 | 0.160925 | -0.124722 | 0.72456 | 0.00002 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000956 |
BRD-K13662825-001-07-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.250645 | 0.547762 | 0.175992 | 0.577077 | 0.009509 | 0.033864 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000956 |
BRD-K14109347-001-03-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.137206 | -0.351047 | -0.177682 | 1 | 5.253934 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000956 |
BRD-K15179879-001-03-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.259688 | 1.784983 | 0.803783 | 0.504335 | 0.015043 | 0.022678 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000956 |
BRD-K15600710-066-05-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.271952 | 0.583216 | 0.235235 | 0.61466 | 0.055688 | 0.213971 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000956 |
BRD-K16730910-001-10-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.809032 | 2.318393 | 0.15338 | 0.94585 | 0.638583 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000956 |
BRD-K17555800-003-02-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.110456 | -0.130554 | -0.085314 | 1 | 0.042477 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000956 |
BRD-K17610631-001-03-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.792375 | -7.848059 | 0.140387 | 0.955607 | 0.004707 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000956 |
BRD-K17743125-001-08-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.163069 | 6.891936 | 0.651309 | 0.842514 | 1.610358 | 1.705282 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000956 |
BRD-K17894950-001-14-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.889572 | 1.50482 | 0.11626 | 0.924857 | 0.013469 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000956 |
BRD-K18961567-001-01-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.933584 | -0.323323 | -0.053251 | 0.946202 | 14.606807 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000956 |
BRD-K19540840-001-09-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.225975 | 0.045615 | -0.016922 | 1 | 0.000759 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000956 |
BRD-K19687926-001-04-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.762237 | 0.220264 | -0.131368 | 0.842068 | 0.002671 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000956 |
BRD-K19796430-001-05-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.038363 | -0.276357 | -0.185216 | 1 | 0.227809 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000956 |
BRD-K22064724-001-01-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.17131 | 1.876753 | 0.344475 | 0.773166 | 0.70457 | 0.881028 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000956 |
BRD-K22822991-001-02-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.228487 | -0.294383 | 0.079878 | 1 | 0.020824 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000956 |
BRD-K23228615-001-02-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.788595 | 0.645478 | 0.052327 | 0.906173 | 0.141754 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000956 |
BRD-K23984367-001-07-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.650168 | -3.784233 | -0.082369 | 0.879581 | 0.017223 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000956 |
BRD-K26026438-001-01-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.923668 | 1.504565 | 0.074381 | 0.94483 | 0.008886 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000956 |
BRD-K26657438-001-15-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.042464 | -0.124273 | -0.009285 | 1 | 3.662629 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000956 |
BRD-K28822270-001-03-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.168129 | 1.315012 | 0.659177 | 0.740913 | 0.516842 | 0.70586 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000956 |
BRD-K29905972-001-06-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.700252 | -1.431035 | -0.315102 | 0.809079 | 0.296304 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000956 |
BRD-K30577245-001-05-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.069774 | 0.70236 | 0.581274 | 0.684579 | 0.026567 | 0.032907 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000956 |
BRD-K31698212-001-02-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.80973 | 1.579063 | 0.011725 | 0.954024 | 0.973738 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000956 |
BRD-K31928526-001-02-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.579024 | 0.396972 | 0.279527 | 1 | 0.047859 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000956 |
BRD-K33379087-001-07-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.554879 | 2.999429 | 0.065366 | 0.836055 | 0.280331 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000956 |
BRD-K33610132-001-02-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.731348 | 0.467629 | -0.029375 | 0.806621 | 0.004974 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000956 |
BRD-K33622447-066-01-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.53727 | 2.129946 | 0.421484 | 0.901063 | 1.262781 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000956 |
BRD-K35520305-001-16-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.854817 | -2.749351 | 0.130362 | 0.919431 | 0.13312 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000956 |
BRD-K36627727-001-05-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.372485 | 0.104808 | -0.44328 | 0.642013 | 0.004915 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000956 |
BRD-K36788280-001-01-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.204936 | 1.168571 | -0.149552 | 1 | 0.177321 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000956 |
BRD-K37379014-001-02-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.220839 | 6.183 | 0.245223 | 1 | 0.000792 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000956 |
BRD-K38332599-001-01-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.177849 | 12.844413 | 0.584974 | 0.828783 | 1.325176 | 1.371314 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000956 |
BRD-K38527262-300-01-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.311421 | 0.000754 | -0.288902 | 0.655807 | 0.075825 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000956 |
BRD-K38852836-001-02-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.391507 | 2.591987 | 0.404784 | 0.766977 | 0.060881 | 0.109773 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000956 |
BRD-K39974922-001-04-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.589793 | -1.281689 | 0.028126 | 1 | 0.004738 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000956 |
BRD-K41859756-001-06-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.601375 | 8.329491 | 0.064897 | 0.686653 | 0.001219 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000956 |
BRD-K42495768-001-01-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.767485 | -5.199282 | 0.205812 | 0.889893 | 0.06042 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000956 |
BRD-K42805893-001-04-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.547562 | 0.707277 | 0.22038 | 0.842053 | 0.380361 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000956 |
BRD-K42828737-001-03-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.782233 | -0.28561 | -0.045614 | 0.88546 | 0.118936 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000956 |
BRD-K42898655-001-01-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.700841 | -0.330517 | -0.249362 | 0.819534 | 0.022409 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000956 |
BRD-K43389675-001-02-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.098651 | 3.855408 | 0.690242 | 0.668657 | 0.282264 | 0.298822 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000956 |
BRD-K44227013-001-06-4 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.17685 | 7.115497 | -0.034326 | 1 | 0.335984 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000956 |
BRD-K44408410-001-17-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.266358 | 0.013664 | -0.183422 | 1 | 47,930,266.962462 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000956 |
BRD-K44827188-001-06-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.811248 | 0.128593 | -0.082892 | 0.876372 | 0.000458 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000956 |
BRD-K49328571-001-15-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.828926 | -1.255262 | -0.372868 | 0.975174 | 0.002149 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000956 |
BRD-K49350383-001-14-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.958594 | -0.437184 | -0.021247 | 0.98252 | 0.029707 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000956 |
BRD-K50168500-001-07-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.063108 | -0.126958 | -0.011056 | 1 | 0.14206 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000956 |
BRD-K51313569-001-07-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.850283 | 3.461279 | 0.083824 | 0.949862 | 0.38776 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000956 |
BRD-K51791723-003-01-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.373134 | 0.940768 | -0.026182 | 0.715408 | 0.123249 | 0.529553 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000956 |
BRD-K51967704-001-03-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.867381 | -2.021442 | -0.158685 | 0.878258 | 5.038622 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000956 |
BRD-K52313696-001-12-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | -0.136071 | -0.817575 | 0.018601 | 0.962493 | 0.00014 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000956 |
BRD-K53414658-001-08-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.815896 | 0.152776 | -0.159824 | 0.910309 | 0.11095 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000956 |
BRD-K53972329-001-07-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.004073 | -0.080916 | -0.000224 | 1 | 34.038732 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000956 |
BRD-K54256913-001-08-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.989988 | -0.043249 | -0.097315 | 0.993803 | 6,078.545741 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000956 |
BRD-K54955827-001-02-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.79809 | 0.914681 | 0.034319 | 0.914988 | 0.171435 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000956 |
BRD-K54997624-001-06-0 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.938008 | 6.119966 | 0.062253 | 0.951302 | 0.004888 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000956 |
BRD-K55187425-236-05-2 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.180733 | -0.016356 | -0.066782 | 0.593915 | 0.027062 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000956 |
BRD-K56343971-001-14-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.011384 | 0.194295 | -0.007565 | 1 | 0.035941 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000956 |
BRD-K56981171-001-02-8 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.478319 | 2.089436 | -0.026922 | 0.70522 | 0.041538 | 0.186516 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000956 |
BRD-K57080016-001-15-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.414278 | 0.159834 | 0.147461 | 1 | 0.157384 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000956 |
BRD-K57169635-001-04-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.954567 | -0.869425 | -0.059733 | 0.981552 | 0.017056 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000956 |
BRD-K58529924-001-01-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.159343 | 1.875168 | 0.744851 | 0.860124 | 2.1646 | 2.656187 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000956 |
BRD-K58550667-001-08-7 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.303688 | 3.929537 | 0.397196 | 0.866179 | 0.096805 | 0.122809 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000956 |
BRD-K59317601-001-05-5 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.467507 | 1.808982 | 0.493363 | 0.63393 | 0.012635 | 0.057259 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000956 |
BRD-K59369769-001-22-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 2.269483 | 4.656998 | 0.177063 | 1 | 0.100384 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000956 |
BRD-K60866521-001-07-1 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.938161 | -0.206133 | -0.002 | 0.953131 | 29.835479 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000956 |
BRD-K60997853-001-02-3 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.434346 | 0.88905 | -0.080326 | 0.915025 | 3.331778 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000956 |
BRD-K61192372-001-08-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.011011 | -0.240328 | -0.053017 | 1 | 6.1324 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000956 |
BRD-K62008436-001-23-9 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 0.397409 | 4.183634 | 0.755163 | 0.727099 | 0.007709 | 0.011257 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000956 |
BRD-K62196610-001-01-6 | ACH-000956 | 22RV1_PROSTATE | MTS010 | 1 | 1.003634 | 0.0521 | -0.018221 | 1 | 0.001867 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000956 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.